Rather mild phenotype in a patient with homozygous null mutations in the α-sarcoglycan gene

Gian Paolo Ramelli, Franziska Joncourt, Marcella Gasperini, Paola Tonin, Jean Marc Burgunder

Department of Paediatrics, Ospedale San Giovanni Bellinzona, Switzerland
Human Genetics, Children’s University Hospital, Berne, Switzerland
Department of Pneumology, Neuromuscular Service, Verona, Italy
Department of Neurological Sciences and Vision, Section of Clinical Neurology, Verona, Italy
Department of Neurology, University of Berne, Inselspital, Berne, Switzerland

The dystrophin-glycoprotein complex connects the cytoskeleton of a muscle fiber to its extracellular matrix. Most forms of muscular dystrophy are caused by mutations in the dystrophin gene. Mutations in the α-sarcoglycan gene, a further member of the dystrophin-glycoprotein complex, also induce muscular dystrophy. We report the history of a woman with homozygous null mutations in the α-sarcoglycan gene and an unusual disease course.

The patient started to have difficulty running and climbing stairs unassisted at 6 years of age. At age 12 she was unable to walk and was wheelchair bound. At the age of 28 she required nocturnal ventilatory assistance. At the age of 38 she gave birth to a healthy girl by caesarean section. She is currently 43-year-old and presents marked generalised muscle wasting. Serum CK is 498 IU/l (normal: 200 IU/l or less). ECG and echocardiography never revealed an abnormal cardiac rhythm or a pathological myocardial function. The first muscle biopsy, taken from the quadriceps at the age of 16, revealed dystrophic features with a wide variation in fibre size, including fibre hypertrophy and increased endomysial connective tissue. A second biopsy at the age of 38 showed mostly connective tissue.

Figure 1
Immunohistochemistry with antibodies to α-sarcoglycan shows a complete absence of the protein.

Figure 2
Electropherograms showing part of exon 2 of the α-sarcoglycan gene. Upper panel: wild-type sequence. Lower panel: patient’s sequence containing the novel homozygous mutation c.86dupA (arrow).
tissue and fatty cells with only rare muscle cells. Immunohistochemical analysis demonstrated the presence of dystrophin by staining with three antibodies (Dys 1-3, Novocastra) but absence of α-sarcoglycan (figure 1) and abnormally decreased staining of β- and γ-sarcoglycan. Molecular biology studies revealed a previously unreported homozygous mutation in the α-sarcoglycan gene: c.86dupA in exon 2 (figure 2). Patients homozygous for null mutations in the α-sarcoglycan gene tend to present during infancy with a very severe disease [1–3]. The rather benign disease course noted in our patient confirms that caution is needed before drawing conclusions regarding genotype-phenotype correlations.

Correspondence:
G. P. Ramelli
Department of Paediatrics
Ospedale San Giovanni
CH-6500 Bellinzona
Switzerland
E-Mail: gianpaolo.ramelli@eoc.ch

References
2 Duggan DJ, Fanin M, Pegoraro E, Angelini C, Hoffman EP. α-Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations. J Neurol Sci 1996;140:30–9.
The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Editorial Board
- Prof. Jean-Michel Dayer, Geneva
- Prof. Peter Gehr, Berne
- Prof. André P. Perruchoud, Basel
- Prof. Andreas Schaffner, Zurich
  (Editor in chief)
- Prof. Werner Straub, Berne
- Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
- Prof. K. E. Juhani Airaksinen, Turku, Finland
- Prof. Anthony Bayes de Luna, Barcelona, Spain
- Prof. Hubert E. Blum, Freiburg, Germany
- Prof. Walter E. Haefeli, Heidelberg, Germany
- Prof. Nino Kuenzli, Los Angeles, USA
- Prof. René Lutter, Amsterdam, The Netherlands
- Prof. Claude Martin, Marseille, France
- Prof. Josef Patsch, Innsbruck, Austria
- Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch